Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CDMC 2018: Shifting gears in the management of diabetes and CVDBenefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Prof. Eduard Montanya, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Screening for Diabetes: When is it meaningful and how should it be performed
Prof. Lars Rydén
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Prof. Eduard Montanya Barcelona
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
